Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome

Ryotaro Nakamura,Wael Saber,Michael Martens,Alyssa Ramirez,Bart L. Scott,Betul Oran,Eric S. Leifer,Roni Tamari,Asmita Mishra,Richard T. Maziarz,Joseph McGuirk,Peter Westervelt,Sumithira Vasu,Mrinal M Patnaik,Rammurti T. Kamble,Stephen J. Forman,Mikkael A. Sekeres,Frederick R. Appelbaum,Adam Mendizabal,Brent R. Logan,Mary M. Horowitz,Corey Cutler

Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome

2021

PURPOSEAllogeneic hematopoietic cell transplantation (HCT) is the only potentially curative therapy for myelodysplastic syndromes (MDS), although it is infrequently offered to older patients. The r...

Keywords:

Transplantation
older patients
reduced intensity
Medicine
Internal medicine
Myelodysplastic syndromes
in patient
Oncology
Text mining
MEDLINE
hematopoietic cell

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations